Charles Rhyee analyst TD COWEN

Currently out of the existing stock ratings of Charles Rhyee, 292 are a BUY (73%), 103 are a HOLD (25.75%), 5 are a SELL (1.25%).

Charles Rhyee

Work Performance Price Targets & Ratings Chart

Analyst Charles Rhyee, currently employed at TD COWEN, carries an average stock price target met ratio of 67.86% that have a potential upside of 27.3% achieved within 264 days. Previously, Charles Rhyee worked at COWEN.

Charles Rhyee’s has documented 803 price targets and ratings displayed on 52 stocks. The coverage is on Healthcare, Consumer Cyclical, Communication Services, Energy sectors.

Most recent stock forecast was given on MEDP, Medpace Holdings at 24-Jul-2026.

Wall Street Analyst Charles Rhyee

Analyst best performing recommendations are on CSLT (CASTLIGHT HEALTH).
The best stock recommendation documented was for FTRE (FORTREA HOLDINGS) at 8/11/2025. The price target of $7 was fulfilled within 1 day with a profit of $0.61 (9.55%) receiving and performance score of 95.46.

Average potential price target upside

ABC AmerisourceBergen CERN Cerner Corp CHNG Change Healthcare CI Cigna Corp CSLT Castlight Health CVS CVS Health Corp DRIO DarioHealth Corp EVH Evolent Health GDRX Goodrx Holdings  HUM Humana MCK McKesson MDRX Allscripts Healthcare Solutions OTRK Ontrak OWLT Owlet RAD Rite Aid SNCE Science 37 Holdings TDOC Teladoc WBA Walgreens Boots Alliance AMWL American Well Corp RCM R1 RCM CAH Cardinal Health PEAR Pear Therapeutics HLTH Cue Health CNC Centene Corp UNH UnitedHealth Group ATHN athenahealth BTTX Better Therapeutics MOH Molina Healthcare VEEV Veeva Systems WBMD WebMD Health Corp IQV IQVIA Holdings TALK Talkspace CRL Charles River Laboratories ICLR ICON PLC MEDP Medpace Holdings FTRE Fortrea Holdings DPLO Diplomat Pharmacy ANTM Anthem ELV Elevance Health OPCH Option Care Health PINC Premier XNCR Xencor COR Cencora HLT Hilton Worldwide Holdings LVGO Livongo Health MDV Modiv SN SharkNinja W Wayfair WB Weibo Corp AN AutoNation CVX Chevron Corp RC Ready Capital Corp

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 27-Feb-2018

$215

$40.04 (22.89%)

$187

2 years 11 months 25 days ago
(07-Aug-2023)

15/16 (93.75%)

$28.91 (15.54%)

636

Hold Since 27-May-2022

$190

$15.04 (8.60%)

$176

2 years 11 months 29 days ago
(03-Aug-2023)

12/12 (100%)

$-0.86 (-0.45%)

392

Buy Since 11-Oct-2022

$215

$40.04 (22.89%)

$200

2 years 11 months 29 days ago
(03-Aug-2023)

7/10 (70%)

$24.14 (12.65%)

211

Buy Since 05-Aug-2021

$220

$45.04 (25.74%)

$213

2 years 11 months 29 days ago
(03-Aug-2023)

11/17 (64.71%)

$29.14 (15.27%)

326

$190

$15.04 (8.60%)

2 years 11 months 29 days ago
(03-Aug-2023)

9/9 (100%)

$-0.86 (-0.45%)

440

Show more analysts

Please expand the browser size to see the chart

Which stock is Charles Rhyee is most bullish on?

Potential upside of $148.1 has been obtained for MCK (MCKESSON)

Which stock is Charles Rhyee is most reserved on?

Potential downside of -$109.38 has been obtained for MEDP (MEDPACE HOLDINGS)

What Year was the first public recommendation made by Charles Rhyee?

On 2013

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?